

OHSU DEPARTMENT OF RADIATION MEDICINE

CONTINUING MEDICAL EDUCATION

2016 Pacific Northwest Annual Workshop on Methods in Radiation Oncology Clinical Trials

MAY 5–7, 2016

**Collaborative Life Sciences Building
Portland, Ore.**



KNIGHT
CANCER
Institute



2016 Pacific Northwest Annual Workshop on Methods in Radiation Oncology Clinical Trials

May 5 –7, 2016

COURSE DIRECTOR

Charles Thomas Jr., M.D.
Professor and Chair
OHSU Radiation Medicine

COURSE CO-DIRECTORS

Mohamed Khan, M.D., Ph.D.
Division Chief of Radiation Oncology
Banner MD Anderson Cancer Center
Ramesh Rengan, M.D., Ph.D.
Medical Director
SCCA Proton Therapy

COURSE COORDINATOR

Bridgett Sparkman
Executive Specialist

LOCATION

Collaborative Life Science Building
2730 S.W. Moody Ave.
Portland, OR 97239

ACCREDITATION

Oregon Health & Science University
School of Medicine is accredited
by the Accreditation Council for
Continuing Medical Education to
provide continuing medical education
for physicians.

CREDIT

OHSU School of Medicine, Division of
CME, designates this live activity for
a maximum of 11.75 *AMA PRA*
Category 1 Credits™. Physicians should
claim only the credit commensurate
with the extent of their participation
in the activity.

TARGET AUDIENCE

Radiation oncology physicians, residents, fellows and
junior faculty

OBJECTIVES

Following this CME course, participants should be able to
demonstrate the following:

- An ability to define primary and secondary trial aims and appropriate endpoints to measure in radiotherapy clinical trials.
- An ability to define Phase 0, I, II, III, and other clinical trial designs for radiotherapy clinical trials.
- An understanding of the basic clinical trial biostatistics.
- Knowledge of the best practices for image guidance-driven clinical trials.
- An understanding of how to incorporate immune-based endpoints in radiotherapy clinical trial design.
- An understanding of how to incorporate QOLife endpoints in radiotherapy clinical trial design.
- An understanding of the role of clinical informatics in radiotherapy clinical trial design.
- Knowledge of best practices in particle therapy-based clinical trial design.

Faculty

COURSE DIRECTORS

Charles R. Thomas Jr., M.D.

Professor and Chair
Department of Radiation Medicine
OHSU Knight Cancer Institute

Ramesh Rengan, M.D., Ph.D.

Course Co-Director
Medical Director
Seattle Cancer Care Alliance Proton
Therapy

Mohamed Khan, M.D., Ph.D.

Course Co-Director
Division Chief
Banner MD Anderson Cancer Service
Line

OHSU FACULTY

Sophia Bornstein, M.D., Ph.D.

Physician-Scientist
Department of Radiation Medicine
OHSU Knight Cancer Institute

Alex Guimaraes, M.D., Ph.D.

Associate Professor and Section Head
Abdominal Imaging Diagnostic
Radiology
OHSU

Arthur Y. Hung, M.D.

Assistant Professor
Medical Student Clerkship Medicine
Director
Department of Radiation Medicine
OHSU Knight Cancer Institute

Jerry Jaboin, M.D., Ph.D.

Assistant Professor
Department of Radiation Medicine
OHSU Knight Cancer Institute

Elena Korngold, M.D.

Associate Professor
Department of Diagnostic Radiology
OHSU

John Minger

Senior Research Assistant
Department of Radiation Medicine
OHSU Knight Cancer Institute

Timur Mitin, M.D., Ph.D.

Assistant Professor
Department of Radiation Medicine
OHSU Knight Cancer Institute
Medical Director
Tuality/OHSU Cancer Center

VISITING FACULTY

Marka Crittiden, M.D., Ph.D.

Physician-Scientist
Department of Radiation Oncology
The Oregon Clinic

Clifton David Fuller, M.D., Ph.D.

Assistant Professor
Department of Radiation Oncology
The University of Texas
MD Anderson Cancer Center

Michael Gough, Ph.D.

Scientist
Earle A. Chiles Research Institute

Lilie L. Lin, M.D.

Assistant Professor
Department of Radiation Oncology
Hospital of the University of
Pennsylvania

James Moon, M.S.

Biostatistician
Fred Hutchinson Cancer Research
Center

Javier F. Torres-Roca, M.D.

Associate Member
Research and Clinical Trials
Moffitt Cancer Center

Andrew Trister, M.D., Ph.D.

Postdoctoral Fellow
Sage Bionetworks
Resident Physician

Kristina Young, M.D., Ph.D.

Department of Radiation Oncology
The Oregon Clinic

General information



HOWTO ENROLL

Tuition: **\$400** Practicing physicians
\$350 Residents/fellows

Payment can be made by Visa, MasterCard or check.

Register online at www.ohsuknightcancer.com/radcme

Advanced registration closes April 26, 2016.

GENERAL CONTACT INFORMATION

e: cme@ohsu.edu

p: 503 494-8700

f: 503 494-0392

Continuing Medical Education, L-602

Oregon Health & Science University

3181 S.W. Sam Jackson Park Rd.

Portland, OR 97239

For registration questions, please contact:

Bridgett Sparkman

e: sparkmab@ohsu.edu

p: 503 494-1998

DIRECTIONS

www.ohsu.edu/directions

CONFERENCE LOCATION

The course will be held in the Collaborative Life Sciences Building, located in Portland's South Waterfront district, a short tram ride to the main OHSU campus on Marquam Hill.

Collaborative Life Sciences Building, 2370 S.W. Moody Ave. Portland, OR 97239

OHSU KNIGHT CANCER INSTITUTE

With the latest treatments, technologies and clinical trials, we are the only clinical cancer center in Oregon designated by the National Cancer Institute — an honor earned only by the nation's top cancer centers.

ACCOMMODATIONS

Participants may stay in the Residence Inn Riverplace in Downtown Portland, located near Tom McCall Waterfront Park and within walking distance to Portland's city center. The Inn provides spacious suites with all the comforts of home and a complimentary hot breakfast buffet. Guests can enjoy walking along the Willamette River, taking the Portland Streetcar to visit many downtown Portland attractions or viewing the city via the Portland Aerial Tram. The hotel is just minutes from OHSU and the Collaborative Life Sciences Building.

To make your reservation, please call **503 552-9500**.



THURSDAY, MAY 5

6:30 p.m.

Registration

7-8 p.m.

Welcome Reception, h'ordeuvres, and course overview.

Residence Inn Marriott Fremont Room

Charles Thomas, M.D.

Ramesh Rengan, M.D., Ph.D.

Mohamed Khan, M.D., Ph.D.

FRIDAY, MAY 6

7 a.m.

Registration/continental breakfast

8 a.m.

Responsibilities of the PI

Charles R. Thomas, M.D.

8:20 a.m.

Primer on Biostatistics for Clinical Trials

James Moon, M.S.

9 a.m.

Phase I-II Radiotherapy-based Clinical Trials:

Design and Endpoints

Ramesh Rengan, M.D., Ph.D.

9:45 a.m.

Image-guided Radiotherapy Clinical Trial Design

Dave Fuller, M.D., Ph.D.

10:20 a.m.

Coffee break and poster review of clinical trials

11 a.m.

Imaging Endpoints in Clinical Trials:

RESIST, PERSIST and Beyond

Elena Korngold, M.D.

11:30 a.m.

Design of Parallel Pathology and Imaging Endpoints

in Radiotherapy-based Clinical Trials

Kristina Young, M.D., Ph.D.

Noon

Lunch

1 p.m.

Discussion of concept sheets

Open discussion, participants will present (5min) a concept

2:10 p.m.

**Incorporation of Novel Translational Research Endpoints
in Clinical Trials**

Mohamed Khan, M.D., Ph.D.

2:35 p.m.

Immune-Based Endpoints in Radiotherapy-based Clinical Trials

Marka Crittenden, M.D., Ph.D.; Michael Gough, Ph.D.

3:10 p.m.

**Normal Tissue Considerations in Design of Radiotherapy
Trial Design**

Charles Thomas, M.D.

3:45 p.m.

Radiosensitivity and Radioresistance Prediction Tools in Trials

Javier Torres-Roca, M.D.

4:30 p.m.


Panel discussion


5:30 p.m.

Adjourn

SATURDAY, MAY 7

7:45 a.m.	Continental breakfast
8:25 a.m.	Clinical Informatics in Radiotherapy Trial Design Dave Fuller, M.D., Ph.D.
9:05 a.m.	Particle Therapy-Based Clinical Trial Design Ramesh Rengan, M.D., Ph.D.
9:45 a.m.	QOLife Endpoints in Clinical Trial Design Lilie Lin, M.D.
10:25 a.m.	Mathematical Modeling in Design of Radiotherapy Time-Dose-Fractionation Andrew Trister, M.D., Ph.D.
11:05 a.m.	Role of the Research Associate in Radiotherapy Clinical Trials John Minger
11:30 a.m.	Lunch
12:30 p.m.	Clinical Trial Design breakout sessions (disease oriented)
	Session 1 GU Radiotherapy Timur Mitin, M.D., Ph.D.
	Session 2 GI Radiotherapy Charles Thomas, M.D.
	Session 3 Soft Tissue and Bone Tumor Arthur Hung, M.D.
	Session 4 Lung Radiotherapy Ramesh Rengan, M.D., Ph.D.
	Session 5 Head and Neck Dave Fuller, M.D., Ph.D.
	Session 6 Palliative Radiotherapy Sophia Bornstein, M.D., Ph.D.
	Session 7 CNS Radiotherapy Jerry Jaboin, M.D.
	Session 8 "TBD" as needed
1:30 p.m.	Panel discussion
2 p.m.	Post-session test and adjourn
	Airport shuttles





OHSU Knight Cancer Institute
3181 S.W. Sam Jackson Park Road
Portland, OR 97239
503 494-8060

